01/07/2016 23:50:13 1-888-992-3836 (toll free) Free Membership Login

Aviragen Therapeutics, Inc. News (NASDAQ:AVIR)

DateTimeSource
Headline
07/01/20164:01PMGLOBEAviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company’s Board of Directors granted to Jonas Niaura, Vice... More...>>
06/28/20169:00AMGLOBEAviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
ATLANTA, June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy. “Jonas brings to Aviragen considerable business development... More...>>
05/26/20164:30PMGLOBEAviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment... More...>>
05/05/20164:01PMGLOBEAviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
ATLANTA, May 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate... More...>>
04/28/20164:01PMGLOBEAviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
ATLANTA, April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to review the Company’s... More...>>
04/28/201611:46AMGLOBEAviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
ATLANTA, April 25, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty... More...>>
04/14/20164:01PMGLOBEAviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
ATLANTA, April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, “Notable Emerging Anti-Viral Agents” as part of the FBR &... More...>>
04/12/20167:00AMGLOBEBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections... More...>>
04/12/20167:00AMGLOBEBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections... More...>>
04/11/20167:00AMGLOBEBiota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
ATLANTA, April 11, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a challenge study of BTA585... More...>>
04/06/20169:00AMGLOBEBiota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
ATLANTA, April 06, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph Patti, PhD will... More...>>
03/17/20166:30AMGLOBEBiota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
ATLANTA, March 17, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics, LLC, a Cambridge-based biopharmaceutical company founded to develop novel therapies... More...>>
03/09/20167:46PMGLOBEBiota Pharmaceuticals to Present at 28th Annual ROTH Conference
ATLANTA, March 07, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph... More...>>
03/09/20167:46PMGLOBEBiota Announces Positive Results From Phase 1 Program for Direct Acting RSV Antiviral BTA585
ATLANTA, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today top-line safety and pharmacokinetic (PK) data from the Phase... More...>>
03/02/20168:23AMPRNUSShareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of Rockwell Medical, Inc., AAC Holdings, Inc., Dr....
Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of Rockwell Medical, Inc., AAC Holdings, Inc., Dr. Reddy's Laboratories Ltd. and Biota Pharmaceuticals, Inc,; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights PR Newswire SAN DIEGO, March 2, 2016 SAN DIEGO... More...>>
02/16/20169:00AMGLOBEBiota Receives FDA Fast Track Designation for Its Antiviral BTA585 for the Treatment of Respiratory Syncytial Virus Infection...
ATLANTA, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that the U.S. Food and Drug Administration (FDA) granted Fast... More...>>
02/08/20167:00AMGLOBEBiota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma
ATLANTA, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that the first patient has been dosed in a Phase 2 double-blind... More...>>
02/05/20167:00AMGLOBEBiota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results
ATLANTA, Feb. 05, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments. “I am very pleased... More...>>
01/29/20169:00AMGLOBEBiota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2016 Financial Results on February 5, 2016...
ATLANTA, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference... More...>>
12/18/20157:00AMGLOBEBiota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585 
ATLANTA, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it completed an initial Phase 1 single ascending dose... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20160702 03:50:15